Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections – Pipeline Review, H2 2016, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.
Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 29 and 21 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 5 and 4 molecules, respectively.
Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Bharat Biotech International Ltd
Biken Inc
BioCryst Pharmaceuticals Inc
Biotron Ltd
CaroGen Corp
Codagenix Inc
Ennaid Therapeutics LLC
Etubics Corp
GeneOne Life Science, Inc.
GeoVax Labs Inc
Hawaii Biotech Inc
Hemispherx Biopharma Inc
HSRx Group
Humabs BioMed SA
Immunovaccine Inc
Kineta Inc
Mymetics Corp
NewLink Genetics Corp
Novavax Inc
OXIS International Inc
PaxVax Inc
Pharos Biologicals LLC
Plex Pharmaceuticals Inc
Prokarium Ltd
Protein Sciences Corp
Regeneron Pharmaceuticals Inc
Replikins Ltd
Sanofi Pasteur SA
Sirnaomics Inc
Spotlight Innovation Inc
Starpharma Holdings Ltd
Takeda Pharmaceutical Company Ltd
Tamir Biotechnology Inc
TGV-Laboratories
Themis Bioscience GmbH
Valneva SE
Vaxart Inc
VaxInnate Corp
VBI Vaccines Inc
Visterra Inc
VLP Therapeutics LLC
